Vivoryon Therapeutics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
MorphoSys AG, Planegg, Germany informed us on November 04, 2019 pursuant to Art. 43(1) WpHG thereby making reference to the exceedance of the threshold of 10% or a higher threshold from October 25, 2019 , as follows:The investment is used to implement strategic objectives. The reporting person does not intend to obtain further voting rights by acquisition or any other way. The reporting person does not intend to influence the composition of the issuers' administration, management or supervisory board. The reporting person does not intend to change the capital structure of the company, especially with regards to the ratio of internal/outside financing and the dividend policy. Concerning the source of funds, the capital is financed by 100% through equity capital with which the reporting person needs to finance the acquisition of the voting rights.
07.11.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: Vivoryon Therapeutics AG Weinbergweg 22 06120 Halle/Saale
Germany Internet: www.vivoryon.com End of News DGAP News Service